JP2018526412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526412A5 JP2018526412A5 JP2018512858A JP2018512858A JP2018526412A5 JP 2018526412 A5 JP2018526412 A5 JP 2018526412A5 JP 2018512858 A JP2018512858 A JP 2018512858A JP 2018512858 A JP2018512858 A JP 2018512858A JP 2018526412 A5 JP2018526412 A5 JP 2018526412A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hgf
- hgf agent
- medicament
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021130457A JP2021181472A (ja) | 2015-09-11 | 2021-08-10 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
| JP2023179927A JP2023179739A (ja) | 2015-09-11 | 2023-10-19 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
| JP2025157838A JP2025181979A (ja) | 2015-09-11 | 2025-09-24 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217611P | 2015-09-11 | 2015-09-11 | |
| US62/217,611 | 2015-09-11 | ||
| PCT/US2016/050945 WO2017044743A1 (en) | 2015-09-11 | 2016-09-09 | Compositions and methods for prevention and treatment of corneal haze and scarring |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130457A Division JP2021181472A (ja) | 2015-09-11 | 2021-08-10 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526412A JP2018526412A (ja) | 2018-09-13 |
| JP2018526412A5 true JP2018526412A5 (https=) | 2019-10-17 |
| JP6929273B2 JP6929273B2 (ja) | 2021-09-01 |
Family
ID=58240852
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512858A Active JP6929273B2 (ja) | 2015-09-11 | 2016-09-09 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
| JP2021130457A Pending JP2021181472A (ja) | 2015-09-11 | 2021-08-10 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
| JP2023179927A Pending JP2023179739A (ja) | 2015-09-11 | 2023-10-19 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
| JP2025157838A Pending JP2025181979A (ja) | 2015-09-11 | 2025-09-24 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130457A Pending JP2021181472A (ja) | 2015-09-11 | 2021-08-10 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
| JP2023179927A Pending JP2023179739A (ja) | 2015-09-11 | 2023-10-19 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
| JP2025157838A Pending JP2025181979A (ja) | 2015-09-11 | 2025-09-24 | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10449234B2 (https=) |
| EP (2) | EP3347034B1 (https=) |
| JP (4) | JP6929273B2 (https=) |
| AU (3) | AU2016320905B2 (https=) |
| CA (1) | CA2999511C (https=) |
| ES (1) | ES2983338T3 (https=) |
| WO (1) | WO2017044743A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2999511C (en) | 2015-09-11 | 2024-01-23 | The Schepens Eye Research Institute, Inc. | Compositions and methods for prevention and treatment of corneal haze and scarring |
| WO2019155833A1 (ja) * | 2018-02-07 | 2019-08-15 | 学校法人日本医科大学 | 改良型アデノ随伴ウイルスベクター |
| EP3863715A4 (en) * | 2018-10-09 | 2022-08-24 | The Board of Trustees of the Leland Stanford Junior University | MODIFIED FIBROBLASTIC GROWTH FACTOR VARIANTS COMBINED WITH MODIFIED HEPATOCYTE GROWTH FACTOR VARIANTS FOR THERAPY |
| WO2020185689A1 (en) * | 2019-03-08 | 2020-09-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Multilayer drug delivery coating for contact lens |
| EP3962511A4 (en) * | 2019-04-29 | 2023-01-18 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF OCULAR TREATMENT USING A GENETICALLY MODIFIED HEPATOCYTE GROWTH FACTOR DIMERIC FRAGMENT |
| EP4574211A3 (en) | 2021-05-14 | 2025-09-10 | Claris Biotherapeutics, Inc. | Compositions of growth factor for the treatment of eye disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566098B1 (en) * | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
| US5703047A (en) * | 1992-09-21 | 1997-12-30 | Board Of Regents, The University Of Texas System | Methods and treatments for corneal healing with growth factors |
| US5589451A (en) | 1992-09-21 | 1996-12-31 | Board Of Regents, The University Of Texas System | Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors |
| JP3962097B2 (ja) * | 1994-03-18 | 2007-08-22 | 敏一 中村 | 免疫抑制剤による副作用の軽減剤 |
| US20020136721A1 (en) * | 1998-02-17 | 2002-09-26 | Schwall Ralph H. | Hepatocyte growth factor receptor antagonists and uses thereof |
| AU2745599A (en) | 1998-03-05 | 1999-09-20 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| US20030148950A1 (en) * | 2001-10-09 | 2003-08-07 | Li Xin | Kringle domain 1 of human hepatocyte growth factor and uses therefor |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| AU2003270118A1 (en) * | 2002-08-30 | 2004-03-19 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
| US8575099B2 (en) * | 2006-04-20 | 2013-11-05 | Osaka University | Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof |
| JP5093783B2 (ja) * | 2006-04-20 | 2012-12-12 | クリングルファーマ株式会社 | Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質 |
| US20070167935A1 (en) * | 2007-01-19 | 2007-07-19 | Serdarevic Olivia N | Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea |
| US9556248B2 (en) * | 2010-03-19 | 2017-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists |
| HRP20191711T1 (hr) | 2011-03-14 | 2019-12-13 | Drug Delivery Solutions Ltd | Oftalmološki pripravak |
| US8999938B2 (en) * | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
| CA2999511C (en) | 2015-09-11 | 2024-01-23 | The Schepens Eye Research Institute, Inc. | Compositions and methods for prevention and treatment of corneal haze and scarring |
-
2016
- 2016-09-09 CA CA2999511A patent/CA2999511C/en active Active
- 2016-09-09 EP EP16845118.5A patent/EP3347034B1/en active Active
- 2016-09-09 US US15/759,203 patent/US10449234B2/en active Active
- 2016-09-09 AU AU2016320905A patent/AU2016320905B2/en active Active
- 2016-09-09 ES ES16845118T patent/ES2983338T3/es active Active
- 2016-09-09 EP EP24174882.1A patent/EP4417259A3/en active Pending
- 2016-09-09 WO PCT/US2016/050945 patent/WO2017044743A1/en not_active Ceased
- 2016-09-09 JP JP2018512858A patent/JP6929273B2/ja active Active
-
2019
- 2019-10-18 US US16/657,913 patent/US20200121758A1/en not_active Abandoned
-
2021
- 2021-04-20 US US17/235,653 patent/US11759499B2/en active Active
- 2021-08-10 JP JP2021130457A patent/JP2021181472A/ja active Pending
- 2021-12-17 AU AU2021286438A patent/AU2021286438B2/en active Active
-
2023
- 2023-06-01 US US18/327,544 patent/US20240123032A1/en active Pending
- 2023-10-19 JP JP2023179927A patent/JP2023179739A/ja active Pending
-
2025
- 2025-03-04 AU AU2025201563A patent/AU2025201563A1/en active Pending
- 2025-09-24 JP JP2025157838A patent/JP2025181979A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526412A5 (https=) | ||
| US8187608B2 (en) | Treatment of Fibrosis related disorders | |
| JP2010505946A (ja) | 神経再生改善のための補体阻害 | |
| EP2961426B1 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g | |
| KR20110031962A (ko) | 포유류 베타 방어소를 이용한 염증 질환의 치료 | |
| JP7330510B2 (ja) | 非滲出型または萎縮型の黄斑変性にて以前に失われた視力を回復させるための医薬組成物 | |
| Ziebell et al. | Nogo presence is inversely associated with shifts in cortical microglial morphology following experimental diffuse brain injury | |
| JP2025181979A (ja) | 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 | |
| JP2023522208A5 (https=) | ||
| Hong et al. | Effect of substance P on recovery from laser‐induced retinal degeneration | |
| CN105288598A (zh) | 治疗缺氧诱导因子(hif)相关的状况的方法 | |
| He et al. | C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus | |
| US20200087362A1 (en) | Fusion protein slit2d2(c386s)-hsa and use thereof in prevention and/or treatment of lung inflammation | |
| US20240115667A1 (en) | Diphenhydramine and lactoferrin for prevention and treatment of covid-19 | |
| Ahmed et al. | A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis | |
| Fajnkuchen et al. | Evaluation of a new matrix regenerating agent in patients with Sjögren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases | |
| CN108721314A (zh) | 化合物epz5676及其相关抑制剂在制备防治肺纤维化疾病药物中的用途 | |
| CN103301444B (zh) | 重组人胸腺素alpha原蛋白的新用途 | |
| EP4346866A1 (en) | Peptides and methods of use | |
| BR112022003508A2 (pt) | Métodos para restaurar a função lisossômica de células epiteliais de pigmento da retina por ativação de tfeb | |
| JP2021512917A5 (https=) | ||
| US20240307220A1 (en) | Combination Therapy to Treat Temperature Sensitive Mutant Tumors | |
| JP4313033B2 (ja) | 眼科用治療組成物 | |
| JP2015140327A (ja) | 水晶体硬化抑制剤 | |
| RU2788097C2 (ru) | Терапевтические и нейропротекторные пептиды |